Bullboard - Stock Discussion Forum Nevis Brands Inc NEVIF

Primary Symbol: C.NEVI

Consumer Defensive Household & Personal Products

Nevis Brands Inc., formerly Pascal Biosciences Inc., provides cannabis brands throughout the United States. The Company provides products in Washington, Oregon, California, Ohio, Arizona and Colorado through partners and licensees. Its products include Major, which is a cannabis beverage. Major is a high-dose tetrahydrocannabinol (THC) beverage that delivers a consistent cannabis experience... see more

Add To Watchlist

CSE:NEVI - Post Discussion

Nevis Brands Inc > ===========> (PAS.V) BIG NEWS! <=============

View:

Post by Pierretraderman on Nov 10, 2020 8:43am

===========> (PAS.V) BIG NEWS! <=============

Pascal Biosciences Appoints Mark van der Horst as Vice President of Corporate Communications.

https://www.accesswire.com/615679/Pascal-Biosciences-Appoints-Mark-van-der-Horst-as-Vice-President-of-Corporate-Communications

https://www.stockwatch.com/News/Item?bid=Z-C:PAS-2986880&symbol=PAS&region=C

2020-11-10 08:01 ET - News Release

SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / November 10, 2020 / Pascal Biosciences Inc. (TSXV:PAS)(OTC PINK:BIMUF) ("Pascal" or the "Company") today announced the appointment of Mark van der Horst to the position of Vice President of Corporate Communications.

Mr. van der Horst has been CEO and President of several British Columbia companies including Gale Capital, an investment relations firm in Vancouver. Mr. van der Horst will implement an investor relations program, identify a communication strategy and communicate with retail broker contacts to enhance corporate recognition and increase awareness and interest in the Company.

"We are very pleased to welcome Mark to Pascal," said Patrick Gray, CEO. "He has previously done a great job increasing awareness for other companies, and his expertise will help create significant value for our shareholders."

About Pascal Biosciences Inc.
Pascal is a biotechnology company advancing innovative therapies for serious diseases, including COVID-19 and cancer. Pascal's leading cannabinoid is presently in preclinical development for COVID-19, having demonstrated striking efficacy in multiple SARS-CoV-2 infectivity assays. Pascal's strong commitment to cancer therapy is reflected its oncology portfolio. The three major programs include two small molecule therapeutics: PAS-403, which is advancing into clinical trials for the treatment of glioblastoma; and PAS-393, an immuno-stimulatory cannabinoid to be used in combination with checkpoint inhibitor therapy. Pascal is also developing a uniquely specific, targeted therapy for acute lymphoblastic leukemia. For more information, visit www.pascalbiosciences.com.

ON BEHALF OF THE BOARD OF DIRECTORS
Dr. Patrick W. Gray, CEO

Investors:
mark@pascalbiosciences.com

Media Contact:
Mark van der Horst
info@pascalbiosciences.com
Tel: 604-200-1480

182